Non-invasive prenatal screening (NIPS) offers high-risk obstetric patients a noninvasive way to determine the risk of birth defects through a blood test. This is achieved by measuring traces of fetal DNA found in maternal blood; the test can detect fetal aneuploidies with excellent accuracy across all common fetal chromosomal abnormalities. Provides invaluable insight to patient for taking informed decisions with regard to electing CVS or amniocentesis (invasive) versus Non-invasive prenatal screening (NIPS) method

It is used as 1st tier screening test for high-risk pregnancy or 2nd tier screening for general and high-risk pregnancy

Advantage of NIPT Test

  1. Higher positive predictive value (PPV) than MSS, NT, or a combination of both
  2. Non-invasive prenatal screening (NIPS) can be performed from as early as 10 weeks’ gestation.
  3. Whole genome massively parallel shotgun sequencing (MPSS)
  4. Binary positive/negative result for core trisomies (T21, T18, T13)

Specimen Requirement: 

Gestation Age for Screening (weeks): 9-10 weeks (can be done till term)

Detection Rate (DR) for Trisomy 21 (%): 99%

Advantage: Highest Detection Rate; Can be performed as early as 9-10 weeks’ gestation

Methodology: Next Generation Sequencing (massively parallel, MPSS/SNP) of Cell-free DNA from dead trophoblast cells in maternal blood

Sample Type: Maternal Blood in Special Streck (Black) Tube

As a company we believe in philosophy of adoption of advanced genetics technologies with clinical annotation (medical knowledge) that can improve clinical outcomes for patients. This approach has already been proved beneficial for patient’s undergoing diagnosis.

Copyright © 2021 CYTOGeNeOM

Powered by CYTOGeNeOM